Frontiers in Immunology (Mar 2019)

Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2

  • Christian Klemann,
  • Christian Klemann,
  • Nadezhda Camacho-Ordonez,
  • Nadezhda Camacho-Ordonez,
  • Linlin Yang,
  • Zoya Eskandarian,
  • Jessica L. Rojas-Restrepo,
  • Natalie Frede,
  • Alla Bulashevska,
  • Maximilian Heeg,
  • Maximilian Heeg,
  • Moudjahed Saleh Al-Ddafari,
  • Moudjahed Saleh Al-Ddafari,
  • Julian Premm,
  • Maximilian Seidl,
  • Maximilian Seidl,
  • Sandra Ammann,
  • Sandra Ammann,
  • Roya Sherkat,
  • Nita Radhakrishnan,
  • Klaus Warnatz,
  • Susanne Unger,
  • Robin Kobbe,
  • Anja Hüfner,
  • T. Ronan Leahy,
  • Winnie Ip,
  • Winnie Ip,
  • Siobhan O. Burns,
  • Siobhan O. Burns,
  • Manfred Fliegauf,
  • Manfred Fliegauf,
  • Bodo Grimbacher,
  • Bodo Grimbacher

DOI
https://doi.org/10.3389/fimmu.2019.00297
Journal volume & issue
Vol. 10

Abstract

Read online

Non-canonical NF-κB-pathway signaling is integral in immunoregulation. Heterozygous mutations in NFKB2 have recently been established as a molecular cause of common variable immunodeficiency (CVID) and DAVID-syndrome, a rare condition combining deficiency of anterior pituitary hormone with CVID. Here, we investigate 15 previously unreported patients with primary immunodeficiency (PID) from eleven unrelated families with heterozygous NFKB2-mutations including eight patients with the common p.Arg853* nonsense mutation and five patients harboring unique novel C-terminal truncating mutations. In addition, we describe the clinical phenotype of two patients with proximal truncating mutations. Cohort analysis extended to all 35 previously published NFKB2-cases revealed occurrence of early-onset PID in 46/50 patients (mean age of onset 5.9 years, median 4.0 years). ACTH-deficiency occurred in 44%. Three mutation carriers have deceased, four developed malignancies. Only two mutation carriers were clinically asymptomatic. In contrast to typical CVID, most patients suffered from early-onset and severe disease manifestations, including clinical signs of T cell dysfunction e.g., chronic-viral or opportunistic infections. In addition, 80% of patients suffered from (predominately T cell mediated) autoimmune (AI) phenomena (alopecia > various lymphocytic organ-infiltration > diarrhea > arthritis > AI-cytopenia). Unlike in other forms of CVID, auto-antibodies or lymphoproliferation were not common hallmarks of disease. Immunophenotyping showed largely normal or even increased quantities of naïve and memory CD4+ or CD8+ T-cells and normal T-cell proliferation. NK-cell number and function were also normal. In contrast, impaired B-cell differentiation and hypogammaglobinemia were consistent features of NFKB2-associated disease. In addition, an array of lymphocyte subpopulations, such as regulatory T cell, Th17-, cTFH-, NKT-, and MAIT-cell numbers were decreased. We conclude that heterozygous damaging mutations in NFKB2 represent a distinct PID entity exceeding the usual clinical spectrum of CVID. Impairment of the non-canonical NF-κB pathways affects function and differentiation of numerous lymphocyte-subpopulations and thus causes a heterogeneous, more severe form of PID phenotype with early-onset. Further characteristic features are multifaceted, primarily T cell-mediated autoimmunity, such as alopecia, lymphocytic organ infiltration, and in addition frequently ACTH-deficiency.

Keywords